98%
921
2 minutes
20
Background: Primary idiopathic lymphedema is an uncommon condition that typically affects the lower extremities. Patients have a malformed lymphatic system that causes subcutaneous fluid and adipose deposition. Rarely, the disease also has been described in the upper extremities. The purpose of this study was to investigate a cohort of patients with primary arm lymphedema to better understand the disease.
Methods: Patients evaluated in our Lymphedema Program between 2008 and 2018 were reviewed for individuals with upper extremity primary lymphedema. Gender, age of onset, morbidity, associated features, and management were identified. Transit of radiolabeled tracer and dermal backflow on lymphoscintigraphy were recorded.
Results: Twenty-three patients of 234 individuals with primary lymphedema had upper extremity disease (9.8%). Eleven subjects were male. Age of onset was infancy (n = 15), adolescence (n = 5), or adulthood (n = 3). The disease affected the left arm (n = 11), right arm (n = 9), or both upper extremities (n = 3). Lymphoscintigraphy in 15 patients exhibited delayed transit of tracer and 2 illustrated dermal backflow. One-half of individuals also had primary lower extremity lymphedema (six unilateral and six bilateral). None of the patients in the cohort exhibited a family history of lymphedema. Two individuals had Turner syndrome. Morbidity included infection (n = 5), other lymphatic anomalies (n = 6), and lymphangiosarcoma (n = 1).
Conclusions: The upper extremities are a rare location for primary lymphedema and patients often also have lymphedema of the legs. Compared with that of the lower extremities, primary disease of the arm is more likely to be associated with systemic lymphatic dysfunction and has a lower risk of familial transmission.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/lrb.2017.0085 | DOI Listing |
J Int Med Res
September 2025
Department of Hepatobiliary Surgery, The Affiliated People's Hospital of Ningbo University, China.
This study explores effective treatment methods for chronic secondary lymphedema after radical cervical cancer surgery combined with pelvic lymphadenectomy. In cases where conservative treatment was ineffective, we investigated whether multiple injections of indocyanine green can effectively improve the outcomes of lymphatic-venous anastomosis under microscopy. Preoperative lymphatic imaging was used to localize functional vessels, guiding distal left lower limb lymphatic reconstruction.
View Article and Find Full Text PDFPLoS Negl Trop Dis
September 2025
Unit of Clinical and Molecular Medicine, ICMR-Vector Control Research Centre (VCRC), Indira Nagar, Puducherry, India.
Background: Filarial lymphedema, caused by lymphatic filariasis, is characterized by chronic swelling and recurrent skin infections. Acute adenolymphangitis (ADL) episodes significantly exacerbate morbidity. Diabetes mellitus (DM) increases susceptibility to infections; however, the relationship between diabetes and ADL frequency and severity in filarial lymphedema patients remains unclear.
View Article and Find Full Text PDFExp Cell Res
September 2025
Department of Microsurgery, Orthopedic Trauma and Hand Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China. Electronic address:
Promoting lymphatic vessel regeneration is an important method for repairing lymphedema. SOX18 can regulate lymphatic vessel development and plays a crucial role in promoting lymphatic vessel generation. This study aims to demonstrate the role of SOX18 in regulating lymphatic vessel regeneration for the repair of lymphedema and explore its related molecular mechanism.
View Article and Find Full Text PDFDisabil Rehabil
September 2025
Department of Rehabilitation Sciences and Physiotherapy, University of Leuven, Leuven, Belgium.
Purpose: This study aims to cross-culturally validate the Dutch version of the Lymphedema Symptom Intensity and Distress Survey-Head and Neck version 2.0 (LSIDS-H&N v2.0).
View Article and Find Full Text PDFEur J Pharm Biopharm
September 2025
Drug Research Program, Faculty of Pharmacy, University of Helsinki, Finland; Individualized Drug Therapy Research Program, University of Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland; Helsinki One Health, Helsinki, Finland. Electronic address:
Vascular Endothelial Growth Factor C (VEGFC) is a promising biological drug, with preclinical studies indicating its potential for treating myocardial infarction, neurodegenerative diseases, and lymphedema, a condition that currently lacks curative treatment. While adenoviral VEGFC gene therapy has progressed to phase II studies, its clinical efficacy is limited by rapid immune inactivation. This study explores lignin nanoparticles (LNPs) as an alternative VEGFC delivery system.
View Article and Find Full Text PDF